1. Home
  2. SAFE vs NVAX Comparison

SAFE vs NVAX Comparison

Compare SAFE & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safehold Inc. New

SAFE

Safehold Inc. New

HOLD

Current Price

$13.49

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.16

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAFE
NVAX
Founded
2016
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.6B
IPO Year
1999
1996

Fundamental Metrics

Financial Performance
Metric
SAFE
NVAX
Price
$13.49
$8.16
Analyst Decision
Hold
Hold
Analyst Count
11
9
Target Price
$18.82
$11.33
AVG Volume (30 Days)
254.4K
3.7M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
5.23%
N/A
EPS Growth
7.43
309.76
EPS
1.59
2.58
Revenue
$385,552,000.00
$1,123,479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.31
N/A
P/E Ratio
$8.50
$3.16
Revenue Growth
5.43
64.69
52 Week Low
$12.76
$5.01
52 Week High
$18.61
$11.85

Technical Indicators

Market Signals
Indicator
SAFE
NVAX
Relative Strength Index (RSI) 33.48 36.25
Support Level $13.48 $8.01
Resistance Level $14.29 $8.45
Average True Range (ATR) 0.40 0.54
MACD -0.11 -0.27
Stochastic Oscillator 8.19 14.73

Price Performance

Historical Comparison
SAFE
NVAX

About SAFE Safehold Inc. New

Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: